RCM
XLO icon

RA Capital Management’s Xilio Therapeutics XLO Stock Holding History

RA Capital Management’s Portfolio XLO Stock Details XLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-117,837
Closed -$4.82M – 96
2022
Q2 		$4.82M Sell
117,837
-25,179
-18% -$1.33M 0.13% 72
2022
Q1 		$14.2M Hold
143,016
– – 0.31% 67
2021
Q4 		$32M Buy
+143,016
New +$34.1M 0.56% 52

Other funds holding XLO

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIIC
AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

RA Capital Management's XLO Position: Q3 2022 in Review

RA Capital Management sold out of Xilio Therapeutics (XLO) in Q3 2022, closing a stake of 117,837 shares — an estimated $4.82M sold.

RA Capital Management first reported a position in XLO in Q4 2021 and held it in 3 quarters. The position peaked at $32M in Q4 2021. 29 funds tracked by Wall St. Rank hold XLO as of Q3 2022.

  • RA Capital Management reported no remaining Xilio Therapeutics position as of Q3 2022 after selling out during the quarter.
  • RA Capital Management sold 117,837 Xilio Therapeutics shares in Q3 2022, an estimated $4.82M.
  • RA Capital Management first reported a position in Xilio Therapeutics in Q4 2021 and held it in 3 quarters.
  • RA Capital Management's Xilio Therapeutics position peaked at $32M in Q4 2021.
  • 29 funds tracked by Wall St. Rank held Xilio Therapeutics as of Q3 2022.

Based on RA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.